Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program

Han-Mo Chiu, Sam Li-Sheng Chen, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Jean Ching-Yuan Fann, Yi-Chia Lee, Shin-Liang Pan, Ming-Shiang Wu, Chao-Sheng Liao, Hsiu-Hsi Chen, Shin-Lan Koong, Shu-Ti Chiou, Han-Mo Chiu, Sam Li-Sheng Chen, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Jean Ching-Yuan Fann, Yi-Chia Lee, Shin-Liang Pan, Ming-Shiang Wu, Chao-Sheng Liao, Hsiu-Hsi Chen, Shin-Lan Koong, Shu-Ti Chiou

Abstract

Background: The effectiveness of fecal immunochemical testing (FIT) in reducing colorectal cancer (CRC) mortality has not yet been fully assessed in a large, population-based service screening program.

Methods: A prospective cohort study of the follow-up of approximately 5 million Taiwanese from 2004 to 2009 was conducted to compare CRC mortality for an exposed (screened) group and an unexposed (unscreened) group in a population-based CRC screening service targeting community residents of Taiwan who were 50 to 69 years old. Given clinical capacity, this nationwide screening program was first rolled out in 2004. In all, 1,160,895 eligible subjects who were 50 to 69 years old (ie, 21.4% of the 5,417,699 subjects of the underlying population) participated in the biennial nationwide screening program by 2009.

Results: The actual effectiveness in reducing CRC mortality attributed to the FIT screening was 62% (relative rate for the screened group vs the unscreened group, 0.38; 95% confidence interval, 0.35-0.42) with a maximum follow-up of 6 years. The 21.4% coverage of the population receiving FIT led to a significant 10% reduction in CRC mortality (relative rate, 0.90; 95% confidence interval, 0.84-0.95) after adjustments for a self-selection bias.

Conclusions: This large, prospective Taiwanese cohort undergoing population-based FIT screening for CRC had the statistical power to demonstrate a significant CRC mortality reduction, although the follow-up time was short. Although such findings are informative for health decision makers, continued follow-up of this large cohort will be required to estimate the long-term impact of FIT screening if the covered population is expanded.

Keywords: colorectal cancer; fecal immunochemical testing; mortality reduction; population-based screening.

© 2015 American Cancer Society.

Figures

Figure 1
Figure 1
Workflow of the Taiwanese nationwide colorectal cancer screening program. FIT indicates fecal immunochemical testing.
Figure 2
Figure 2
Comparison of cumulative colorectal cancer mortality for screened subjects (n = 1,160,895) and unscreened subjects (n = 4,256,804): (A) without adjustments for the self-selection bias and (B) with adjustments for the self-selection bias and the increasing incidence trend.

References

    1. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.
    1. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.
    1. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–1371.
    1. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674–1680.
    1. Costantini AS, Martini A, Puliti D, et al. Colorectal cancer mortality in two areas of Tuscany with different screening exposures. J Natl Cancer Inst. 2008;100:1818–1821.
    1. Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107:2152–2159.
    1. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105:2017–2025.
    1. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62–68.
    1. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.
    1. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009;100:1103–1110.
    1. Benson VS, Atkin WS, Green J, et al. International Colorectal Cancer Screening Network. Toward standardizing and reporting colorectal cancer screening indicators on an international level: the International Colorectal Cancer Screening Network. Int J Cancer. 2012;130:2961–2973.
    1. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6:871–876.
    1. Yang KC, Liao CS, Chiu YH, Yen AM, Chen TH. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan. J Med Screen. 2006;13(suppl 1):S8–S13.
    1. Chen TH, Chiu YH, Luh DL, et al. Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer. 2004;100:1734–1743.
    1. Taiwanese Bureau of Health Promotion. Cancer control and prevention. . Accessed May 1, 2015.
    1. Chen LS, Liao CS, Chang SH, Lai HC, Chen TH. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16) J Med Screen. 2007;14:191–199.
    1. Hamilton SR, Vogelstein B, Kudo S. Tumours of the colon and rectum. In: Hamilton SR, Aaltonen LA, editors. World Health Organization Classifications of Tumors: Pathology and Genetics of Tumors of the Digestive System. Lyon, France: IARC; 2000.
    1. Taiwan Cancer Registry. 2013. . Accessed July 5,
    1. Duffy SW, Cuzick J, Tabar L, et al. Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. J R Stat Soc Ser C Appl Stat. 2002;51:235–243.
    1. Tabar L, Yen MF, Vitak B, et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003;361:1405–1410.
    1. Wu JC, Anttila A, Yen AM, et al. Evaluation of breast cancer service screening programme with a Bayesian approach: mortality analysis in a Finnish region. Breast Cancer Res Treat. 2010;121:671–678.
    1. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007:CD001216.
    1. International Cancer Screening Network. Inventory of colorectal cancer screening activities in ICSN countries, May 2008. 2013. . Accessed July 5,
    1. Bowel Cancer Screening Pilot Monitoring and Evaluation Steering Committee. The Australian bowel cancer screening pilot and beyond: final evaluation report. 2013. . Accessed July 5,
    1. Sung JJ, Choi SY, Chan FK, Ching JY, Lau JT, Griffiths S. Obstacles to colorectal cancer screening in Chinese: a study based on the health belief model. Am J Gastroenterol. 2008;103:974–981.
    1. Chiu HM, Lee YC, Tu CH, et al. Association between early-stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol. 2013;11:832–838.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться